Hypomorphic NOTCH1 Expression Alters Cardiomyocyte Cellular Architecture in Hypoplastic Left Heart Syndrome
Preprint
Abstract
Summary: NOTCH1 is a protein involved in cardiac development and mutations in NOTCH1 are implicated in left sided congenital heart disease, including hypoplastic left heart syndrome (HLHS). Therapeutic advances for HLHS patients have been hampered by the absence of suitable experimental models. Here, using human induced pluripotent stem cells (hiPSCs), we have generated a series of CRISPR-edited complex heterozygous hypomorphic mutations in NOTCH1 that recapitulate mutations seen in HLHS patients. These cells demonstrate the downregulation of genes associated with mitochondria, the actin cytoskeleton, and cardiomyocyte development. In addition, these hypomorphic NOTCH1 hiPSCs cells showed an increased propensity to differentiate towards non-cardiomyocyte lineages such as fibroblasts and smooth muscle cells, a finding confirmed in HLHS patient-derived myocardial tissue. Abnormalities in sarcomeric and mitochondrial architecture contributed to decreased ATP production, abnormal calcium transients, and reduced contractility. Using a split nano-luciferase system as a NOTCH1 intracellular reporter, we screened a library of FDA-approved compounds. Auranofin, an agent currently employed for rheumatoid arthritis, was identified as a candidate drug that could rescue impaired differentiation and contractility seen in the hypomorphic NOTCH1 model. These findings point to cell-autonomous abnormalities in hypomorphic NOTCH1 pre-cardiomyocyte cells that can be leveraged to identify potential therapeutic strategies for patients with severe congenital cardiac abnormalities. Highlights: CRISPR edited and patient-derived iPSCs with hypomorphic NOTCH1 expression were used to characterize a cell-based model of hypoplastic left heart syndrome. Hypomorphic NOTCH1 iPSCs have abnormalities in pathways associated with mitochondrial function, actin cytoskeleton, and cardiomyocyte development. Hypomorphic NOTCH1 iPSCs have less pluripotency and tend to skew differentiation away from cardiomyocytes and towards fibroblasts and smooth muscle cells. NOTCH1 is required for cardiac cytoskeletal and mitochondrial architecture, and to preserve contractility and ATP production. A high-throughput drug screen identified auranofin as an agent that may benefit patients with hypoplastic left heart syndrome.Keywords
This publication has 39 references indexed in Scilit:
- Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management StrategiesJACC: Cardiooncology, 2023
- Auranofin: Past to Present, and repurposingInternational Immunopharmacology, 2021
- Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart SyndromeCell Stem Cell, 2020
- NOTCH1-Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient-Specific Phenotypes Detected in Bioengineered CardiogenesisStem Cells, 2017
- Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissuesAdvanced Drug Delivery Reviews, 2016
- 40-Year Follow-Up After the Fontan OperationJACC, 2015
- Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndromeHuman Genetics, 2015
- Auranofin: Repurposing an Old Drug for a Golden New AgeDrugs in R&D, 2015
- Arrhythmias in patients with hypoplastic left heart syndromeAmerican Heart Journal, 2011
- Notch Signaling Is Essential for Ventricular Chamber DevelopmentDevelopmental Cell, 2007